ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BBOT vs UPB // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

BridgeBio Oncology Therapeutics Inc. (NASDAQ) VS. Upstream Bio Inc. (NASDAQ) • 15-METRIC TALLY: BBOT 1 — UPB 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBOT VS. UPB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BBOT UPB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 20.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 6.01 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 UPB /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 20.0 39.5 -19.50 UPB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $185.2M $183.5M $1.7M BBOT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BBOT REV UPB REV BBOT GROSS % UPB GROSS % BBOT FCF UPB FCF
FY 2025 $408.3M $2.9M — — -$114.5M -$133.4M
FY 2024 $226.4M $2.4M — — -$55.1M -$59.7M
FY 2023 $116.7K $2.4M — — — -$37.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBOT // BETA —
UPB // BETA —